4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Non Operating Income for 7 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 13.97% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $18.6 million (down 30.64% YoY), while the FY2025 annual figure was $19.4 million, down 27.94% from the prior year.
• Non Operating Income climbed to $4.9 million in Q1 2026 per FDMT's latest filing, from $4.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $7.5 million in Q2 2024 and bottomed at $54000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $3.9 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 4757.14% — and 2025, when it tumbled 40.88%.
• 4D Molecular Therapeutics' Non Operating Income stood at $1.3 million in 2022, then surged by 225.8% to $4.4 million in 2023, then jumped by 47.54% to $6.4 million in 2024, then dropped by 27.37% to $4.7 million in 2025, then climbed by 3.8% to $4.9 million in 2026.
• Business Quant data shows FDMT's Non Operating Income at $4.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.3 million in Q3 2025.